# United States Neurodevelopmental Outcomes of Zika Virus-Exposed Preschoolers

Want to learn more?
Scan the QR code to read some
highlighted publications and news
articles featuring this study!



Sarah B. Mulkey, MD, PhD1-3, Elizabeth Corn, BS1, Meagan E. Williams, MSPH1, Emily Ansusinha, MA1, Robert H. Podolsky, PhD1, Margarita Arroyave-Wessel, MPH1, Colleen Peyton, DPT4, Michael E. Msall, MD5, Adre J. du Plessis, MBChB, MPH1-3, Roberta L. DeBiasi, MD, MS1,3

### **BACKGROUND**

Children with in utero Zika virus (ZIKV) exposure without congenital Zika syndrome (CZS) may be at risk for neurodevelopmental delays (Mulkey et al., 2020). Outcomes for preschoolage children with in utero ZIKV exposure have not yet been reported in the United States.

#### **OBJECTIVE**

This prospective cohort study was conducted at Children's National to assess differences in neurodevelopment between ZIKV-exposed children without CZS (cases) and healthy, unexposed children (controls) at ages 4-5 years in a United States cohort.

#### **METHODS**

Child development was assessed using the **ZIKV Outcome Toolbox (TABLE 1)** (Mulkey et al., 2022). Standard scores were compared between cohorts. P-values were adjusted using the false discovery rate (FDR).

TABLE 1: ASSESSMENTS AND RESULTS	
ZIKV Outcome Toolbox Assessment	Differences between Cases and Controls
BRIEF-P Behavior Rating Inventory of Executive Function	No differences
MABC  Movement Assessment Battery for Children	Cases showed a trend toward lower performance in all categories and total scores. (composite score FDR p=0.11)
PEDI-CAT  Pediatric Evaluation of Disability Inventory	No differences
BSRA  Bracken School  Readiness Assessment	Cases showed a trend toward lower school readiness in sizes/comparisons, shapes, and total scores.  (FDR p≤0.13)
PPVT Peabody Picture Vocabulary Test	No differences
Parent Surveys  Demographics,  Medical History	Controls (A) had greater parent education than cases (B). (College education: (A) 92% of mothers and 67% of fathers; (B) 64% and 46%, respectively)

## RESULTS (see TABLE 1)

Fourteen cases were evaluated at mean (SD) age 5.0 (0.4) years; 12 controls at 4.8 (0.4) years. Three cases had global developmental delay or autism spectrum disorder and were unable to complete the Toolbox. TABLE 1 outlines differences in standard scores between the remaining cases and controls for each assessment.

#### **CONCLUSIONS**

In utero ZIKV exposure may present risks for neurodevelopmental delays. Higher parent education in controls, small sample size, and COVID-19 may partially explain some outcomes. Continued follow-up is needed to understand long-term impacts; we will follow these cases and controls through age 7 (NICHD: R01HD102445).

**AUTHOR AFFILIATIONS:** <sup>1</sup> Children's National Hospital, Washington, DC <sup>2</sup> Department of Neurology, The George Washington University School of Medicine and Health Sciences, Washington, DC <sup>3</sup> Department of Pediatrics, The George Washington University School of Medicine and Health Sciences, Washington, DC <sup>4</sup> Department of Physical Therapy and Human Movement Sciences, Northwestern University, Chicago, IL <sup>5</sup> University of Chicago Medicine Kennedy Research Center on Intellectual and Neurodevelopmental Disabilities, Chicago IL. **FUNDING:** The study was funded by the **Thrasher Research Fund.** Continued evaluations to age 7 years are funded by the Eunice Kennedy Shriver National Institute Of Child Health & Human Development of the **National Institutes of Health** under Award Number R01HD102445.







